Showering c-MET-dependent cancers with drugs.

Current Opinion in Genetics & Development
Beatrice S Knudsen, G F Vande Woude

Abstract

The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies. Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors (http://www.vai.org/met), contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and HGF/SF participate in all stages of malignant progression and represent promising drug targets in a variety of cancer types, including carcinomas, sarcomas, and brain tumors. While many are in pre-clinical testing, a few inhibitors have entered clinical trials. With hundreds of thousands of potential responding cancers that express c-MET, the interest in this molecule as a drug target is not surprising. However, the cognate c-MET diagnostic tests lag behind. In addition, despite the great enthusiasm based on response rates in phase I trials, there is a need for caution. It is almost without question that combination therapies with c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic tumor response.

References

Jun 1, 1990·Cell·E R Fearon, B Vogelstein
Jan 1, 1993·Journal of Cell Science. Supplement·W BirchmeierJ Behrens
Jan 1, 1996·Acta Anatomica·C BirchmeierB Brand-Saberi
May 15, 1997·The EMBO Journal·G A RodriguesJ Schlessinger
Nov 25, 1998·Proceedings of the National Academy of Sciences of the United States of America·M JeffersG F Vande Woude
Sep 20, 2000·The Journal of Cell Biology·M SachsW Birchmeier
Oct 24, 2000·Oncogene·J H LeeG F Vande Woude
Jun 21, 2001·Proceedings of the National Academy of Sciences of the United States of America·B CaoG F Vande Woude
Aug 29, 2002·Nature Cell Biology·Silvia GiordanoPaolo M Comoglio
Jan 10, 2003·Journal of Cellular Biochemistry·Yu-Wen Zhang, George F Vande Woude
May 3, 2003·Cancer Cell·Selma PennacchiettiPaolo M Comoglio
Oct 14, 2003·Proceedings of the National Academy of Sciences of the United States of America·Yu-Wen ZhangGeorge F Vande Woude
Dec 20, 2003·Nature Reviews. Molecular Cell Biology·Carmen BirchmeierGeorge F Vande Woude
Mar 20, 2004·Science·Martin E M NobleLouise N Johnson
Apr 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Chang-Goo HuhSnorri S Thorgeirsson
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Hadi YazijiAllen M Gown
Jul 14, 2004·Proceedings of the National Academy of Sciences of the United States of America·Malgorzata BorowiakCarmen Birchmeier
Jul 21, 2004·Cancer Cell·Yu-Wen ZhangGeorge F Vande Woude
Nov 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Carrie GraveelGeorge Vande Woude
Feb 3, 2005·Cell Research·Chong Feng Gao, George F Vande Woude
Feb 11, 2005·Cell Cycle·S Kermorgant, P J Parker
Jun 14, 2005·Trends in Molecular Medicine·Simona CorsoSilvia Giordano
Jul 19, 2005·Proceedings of the National Academy of Sciences of the United States of America·Chong-Feng GaoGeorge F Vande Woude
Sep 10, 2005·Nature Biotechnology·Gregory P Adams, Louis M Weiner
Oct 11, 2005·Neuro-oncology·Roger Abounader, John Laterra
Jan 7, 2006·Cancer Research·Monica Kong-BeltranRobert Yauch
Feb 3, 2006·International Journal of Cancer. Journal International Du Cancer·Kunio Matsumoto, Toshikazu Nakamura
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·K Jin KimJohn Laterra

❮ Previous
Next ❯

Citations

May 4, 2012·Archives of Pharmacal Research·Kyung Hee JungSoon-Sun Hong
Mar 1, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·S K Kundu, M Nestor
Apr 2, 2011·Cell Death and Differentiation·A FurlanF Maina
Dec 17, 2010·Nature Reviews. Cancer·C René LeemansRuud H Brakenhoff
Jan 25, 2012·Nature Reviews. Cancer·Ermanno GherardiGeorge Vande Woude
May 9, 2012·Nature Reviews. Clinical Oncology·Solange Peters, Alex A Adjei
Jul 25, 2009·Nature Reviews. Drug Discovery·Pasi A JänneJeff Settleman
Jun 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·Katharine D GruganAnil K Rustgi
Sep 15, 2010·Proceedings of the National Academy of Sciences of the United States of America·Guangjun ZhangNancy Hopkins
Dec 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Qian XieGeorge F Vande Woude
Jan 21, 2011·The Journal of Biological Chemistry·Keith W RickertKevin J Lumb
May 23, 2008·The Journal of Biological Chemistry·Cristina BasilicoPaolo Michieli
Apr 10, 2009·Carcinogenesis·Emanuela MatteucciMaria Alfonsina Desiderio
Jan 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·B J YamamotoJ W Harding
Dec 25, 2012·Genes & Cancer·Ahmed El-Telbany, Patrick C Ma
Dec 6, 2008·Journal of Translational Medicine·Qian XieGeorge F Vande Woude
May 18, 2011·Journal of Translational Medicine·Jinxuan HouShi-Jian Ding
Jun 12, 2010·Biological Chemistry·Henry R MaunRobert A Lazarus
Sep 23, 2014·BMC Cancer·Daniel S W TanN Gopalakrishna Iyer
Aug 2, 2014·Neuro-oncology·Qian XieMichael E Berens
Mar 12, 2009·Expert Review of Anticancer Therapy·Thomas R WebbStephan W Morris
May 13, 2009·The Journal of Cell Biology·Silvia GoldoniRenato V Iozzo
Jan 14, 2012·Expert Opinion on Investigational Drugs·Mariana B A FerreiraEzra E W Cohen
Sep 28, 2010·Expert Opinion on Investigational Drugs·Giulia M StellaPaolo M Comoglio
Jul 5, 2013·Kidney International·Oscar C Y YangPatrick J Pollard
Jan 13, 2016·Archives of Pharmacal Research·Eun-Young KimSung Yun Cho
Mar 31, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sara PrevidiMaria Alfonsina Desiderio
Jan 22, 2010·Medical Hypotheses·Mark F McCartyFrancisco Contreras
Feb 24, 2010·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Frédéric HollandeDominique Joubert
Oct 20, 2009·Trends in Pharmacological Sciences·Yongping Crawford, Napoleone Ferrara
Sep 18, 2009·Trends in Cell Biology·Andrea Z LaiMorag Park
May 18, 2010·International Journal of Cancer. Journal International Du Cancer·Alex-Xianghua ZhouLevent M Akyürek
Mar 15, 2011·International Journal of Cancer. Journal International Du Cancer·Michaela MedováYitzhak Zimmer
Jan 12, 2010·International Journal of Cancer. Journal International Du Cancer·Wenjie DongYunlin Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Carcinosarcoma

Carcinosarcoma is a malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. Discover the latest research on carcinosarcoma here.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte
M Christiane Brahimi-HornJacques Pouysségur
© 2022 Meta ULC. All rights reserved